Composition
- Active ingredients
- SIMVASTATIN 10MG; SITAGLIPTIN PHOSPHATE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- SIMVASTATIN 20MG; SITAGLIPTIN PHOSPHATE EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA202343-005 · Discontinued
- SIMVASTATIN 40MG; SITAGLIPTIN PHOSPHATE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA202343-003 · Discontinued
- SIMVASTATIN 10MG; SITAGLIPTIN PHOSPHATE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletThis page
- SIMVASTATIN 40MG; SITAGLIPTIN PHOSPHATE EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA202343-006 · Discontinued
- SIMVASTATIN 10MG; SITAGLIPTIN PHOSPHATE EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA202343-004 · Discontinued
- SIMVASTATIN 20MG; SITAGLIPTIN PHOSPHATE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TabletNDA202343-002 · Discontinued
Official product information
At a glance
- Brand name
- Juvisync
- Active substance
- simvastatin
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Merck Sharp Dohme
- Status
- Discontinued
- FDA approval
- 7 Oct 2011
- Application
- NDA202343-001